Benchmark Reiterates Speculative Buy on CytoMed Therapeutics, Maintains $5 Price Target
Portfolio Pulse from Benzinga Newsdesk
Benchmark analyst Bruce Jackson has reiterated a Speculative Buy rating on CytoMed Therapeutics (NASDAQ:GDTC) and maintained a $5 price target.
June 11, 2024 | 11:33 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Benchmark analyst Bruce Jackson has reiterated a Speculative Buy rating on CytoMed Therapeutics and maintained a $5 price target.
The reiteration of a Speculative Buy rating and the maintenance of a $5 price target by a reputable analyst can positively influence investor sentiment and potentially drive short-term price appreciation for CytoMed Therapeutics.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100